Mark H Tuszynski1, Jennifer H Yang2, David Barba3, Hoi-Sang U3, Roy A E Bakay4, Mary M Pay2, Eliezer Masliah2, James M Conner2, Peter Kobalka5, Subhojit Roy5, Alan H Nagahara2. 1. Department of Neuroscience, University of California, San Diego, La Jolla2Veterans Affairs Medical Center, San Diego, California. 2. Department of Neuroscience, University of California, San Diego, La Jolla. 3. Department of Neurosurgery, University of California, San Diego, La Jolla. 4. Department of Neurosurgery, Rush University Medical Center, Chicago, Illinois. 5. Department of Neuroscience, University of California, San Diego, La Jolla5Department of Pathology, University of California, San Diego, La Jolla.
Abstract
IMPORTANCE: Alzheimer disease (AD) is the most common neurodegenerative disorder and lacks effective disease-modifying therapies. In 2001, we initiated a clinical trial of nerve growth factor (NGF) gene therapy in AD, the first effort at gene delivery in an adult neurodegenerative disorder. This program aimed to determine whether a nervous system growth factor prevents or reduces cholinergic neuronal degeneration in patients with AD. We present postmortem findings in 10 patients with survival times ranging from 1 to 10 years after treatment. OBJECTIVE: To determine whether degenerating neurons in AD retain an ability to respond to a nervous system growth factor delivered after disease onset. DESIGN, SETTING, AND PARTICIPANTS: Patients in this anatomicopathological study were enrolled in clinical trials from March 2001 to October 2012 at the University of California, San Diego, Medical Center in La Jolla. Ten patients with early AD underwent NGF gene therapy using ex vivo or in vivo gene transfer. The brains of all 8 patients in the first phase 1 ex vivo trial and of 2 patients in a subsequent phase 1 in vivo trial were examined. MAIN OUTCOMES AND MEASURES: Brains were immunolabeled to evaluate in vivo gene expression, cholinergic neuronal responses to NGF, and activation of NGF-related cell signaling. In 2 patients, NGF protein levels were measured by enzyme-linked immunosorbent assay. RESULTS: Among 10 patients, degenerating neurons in the AD brain responded to NGF. All patients exhibited a trophic response to NGF in the form of axonal sprouting toward the NGF source. Comparing treated and nontreated sides of the brain in 3 patients who underwent unilateral gene transfer, cholinergic neuronal hypertrophy occurred on the NGF-treated side (P < .05). Activation of cellular signaling and functional markers was present in 2 patients who underwent adeno-associated viral vectors (serotype 2)-mediated NGF gene transfer. Neurons exhibiting tau pathology and neurons free of tau expressed NGF, indicating that degenerating cells can be infected with therapeutic genes, with resultant activation of cell signaling. No adverse pathological effects related to NGF were observed. CONCLUSIONS AND RELEVANCE: These findings indicate that neurons of the degenerating brain retain the ability to respond to growth factors with axonal sprouting, cell hypertrophy, and activation of functional markers. Sprouting induced by NGF persists for 10 years after gene transfer. Growth factor therapy appears safe over extended periods and merits continued testing as a means of treating neurodegenerative disorders.
IMPORTANCE: Alzheimer disease (AD) is the most common neurodegenerative disorder and lacks effective disease-modifying therapies. In 2001, we initiated a clinical trial of nerve growth factor (NGF) gene therapy in AD, the first effort at gene delivery in an adult neurodegenerative disorder. This program aimed to determine whether a nervous system growth factor prevents or reduces cholinergic neuronal degeneration in patients with AD. We present postmortem findings in 10 patients with survival times ranging from 1 to 10 years after treatment. OBJECTIVE: To determine whether degenerating neurons in AD retain an ability to respond to a nervous system growth factor delivered after disease onset. DESIGN, SETTING, AND PARTICIPANTS: Patients in this anatomicopathological study were enrolled in clinical trials from March 2001 to October 2012 at the University of California, San Diego, Medical Center in La Jolla. Ten patients with early AD underwent NGF gene therapy using ex vivo or in vivo gene transfer. The brains of all 8 patients in the first phase 1 ex vivo trial and of 2 patients in a subsequent phase 1 in vivo trial were examined. MAIN OUTCOMES AND MEASURES: Brains were immunolabeled to evaluate in vivo gene expression, cholinergic neuronal responses to NGF, and activation of NGF-related cell signaling. In 2 patients, NGF protein levels were measured by enzyme-linked immunosorbent assay. RESULTS: Among 10 patients, degenerating neurons in the AD brain responded to NGF. All patients exhibited a trophic response to NGF in the form of axonal sprouting toward the NGF source. Comparing treated and nontreated sides of the brain in 3 patients who underwent unilateral gene transfer, cholinergic neuronal hypertrophy occurred on the NGF-treated side (P < .05). Activation of cellular signaling and functional markers was present in 2 patients who underwent adeno-associated viral vectors (serotype 2)-mediated NGF gene transfer. Neurons exhibiting tau pathology and neurons free of tau expressed NGF, indicating that degenerating cells can be infected with therapeutic genes, with resultant activation of cell signaling. No adverse pathological effects related to NGF were observed. CONCLUSIONS AND RELEVANCE: These findings indicate that neurons of the degenerating brain retain the ability to respond to growth factors with axonal sprouting, cell hypertrophy, and activation of functional markers. Sprouting induced by NGF persists for 10 years after gene transfer. Growth factor therapy appears safe over extended periods and merits continued testing as a means of treating neurodegenerative disorders.
Authors: Michael S Rafii; Tiffany L Baumann; Roy A E Bakay; Jeffrey M Ostrove; Joao Siffert; Adam S Fleisher; Christopher D Herzog; David Barba; Mary Pay; David P Salmon; Yaping Chu; Jeffrey H Kordower; Kathie Bishop; David Keator; Steven Potkin; Raymond T Bartus Journal: Alzheimers Dement Date: 2014-01-07 Impact factor: 21.566
Authors: Jeffrey H Kordower; Christopher D Herzog; Biplob Dass; Roy A E Bakay; James Stansell; Mehdi Gasmi; Raymond T Bartus Journal: Ann Neurol Date: 2006-12 Impact factor: 10.422
Authors: Alan H Nagahara; David A Merrill; Giovanni Coppola; Shingo Tsukada; Brock E Schroeder; Gideon M Shaked; Ling Wang; Armin Blesch; Albert Kim; James M Conner; Edward Rockenstein; Moses V Chao; Edward H Koo; Daniel Geschwind; Eliezer Masliah; Andrea A Chiba; Mark H Tuszynski Journal: Nat Med Date: 2009-02-08 Impact factor: 53.440
Authors: Emrin Horgusluoglu; Kelly Nudelman; Kwangsik Nho; Andrew J Saykin Journal: Am J Med Genet B Neuropsychiatr Genet Date: 2016-02-16 Impact factor: 3.568
Authors: Sourav R Choudhury; Eloise Hudry; Casey A Maguire; Miguel Sena-Esteves; Xandra O Breakefield; Paola Grandi Journal: Neuropharmacology Date: 2016-02-21 Impact factor: 5.250
Authors: Kijung Sung; Luiz F Ferrari; Wanlin Yang; ChiHye Chung; Xiaobei Zhao; Yingli Gu; Suzhen Lin; Kai Zhang; Bianxiao Cui; Matthew L Pearn; Michael T Maloney; William C Mobley; Jon D Levine; Chengbiao Wu Journal: J Neurosci Date: 2018-02-26 Impact factor: 6.167